Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1

Liu,Quan; Zheng,Jie‑Min; Chen,Jia‑Kang; Yan,Xian‑Lei; Chen,Hong‑Mou; Nong,Wei‑Xia; Huang,He‑Qing

doi:10.3892/mmr.2014.2395

Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1

Authors:
- Quan Liu
- Jie‑Min Zheng
- Jia‑Kang Chen
- Xian‑Lei Yan
- Hong‑Mou Chen
- Wei‑Xia Nong
- He‑Qing Huang
View Affiliations

Affiliations: Department of Neurosurgery, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China, Department of Histology and Embryology, School of Basic Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: July 18, 2014 https://doi.org/10.3892/mmr.2014.2395
Pages: 2045-2050

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone deacetylases (HDACs) constitute a family of enzymes that play important roles in the epigenetic regulation of gene expression and contribute to the growth, differentiation and apoptosis of cancer cells. However, the biological function of HDAC5 in glioma cells has not been fully understood. In the present study, we found that the mRNA and protein levels of HDAC5 are increased in human glioma tissues and cell lines. In addition, overexpression of HDAC5 promoted proliferation of glioma cells, as measured by the MTT assay. By contrast, HDAC5 gene silencing using small interfering RNA (siRNA) inhibited cell proliferation. Furthermore, we demonstrated that HDAC5 enhances Notch 1 expression at both the mRNA and the protein level in glioma cell lines. Taken together, these results demonstrated, for the first time to the best of our knowledge, that HDAC5 promotes glioma cell proliferation, and suggest that this effect involves the upregulation of Notch 1. Therefore, our study may provide a novel therapeutic target for treatment of gliomas.

View Figures

View References

1	Medina Villaamil V, Alvarez García A, Aparicio Gallego G, et al: Tissue array analysis for the differentiation of gliosis from gliomas. Mol Med Rep. 4:451–457. 2011.PubMed/NCBI
2	Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
3	Wang Y, Zhou Z, Luo H, et al: Combination of tamoxifen and antisense human telomerase RNA inhibits glioma cell proliferation and anti-apoptosis via suppression of telomerase activity. Mol Med Rep. 3:935–940. 2010.PubMed/NCBI
4	Lefranc F, Facchini V and Kiss R: Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist. 12:1395–1403. 2007. View Article : Google Scholar
5	Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett. 277:8–21. 2009. View Article : Google Scholar : PubMed/NCBI
6	de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 370:737–749. 2003.PubMed/NCBI
7	Voelter-Mahlknecht S, Ho AD and Mahlknecht U: Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int J Mol Med. 16:589–598. 2005.PubMed/NCBI
8	Sen N, Kumari R, Singh MI and Das S: HDAC5, a key component in temporal regulation of p53-mediated transactivation in response to genotoxic stress. Mol Cell. 52:406–420. 2013. View Article : Google Scholar : PubMed/NCBI
9	Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett. 277:8–21. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wiegmans AP, Alsop AE, Bots M, et al: Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res. 71:3603–3615. 2011. View Article : Google Scholar
11	Munster P, Marchion D, Bicaku E, et al: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 15:2488–2496. 2009. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
13	Ronsch K, Jager M, Schopflin A, Danciu M, Lassmann S and Hecht A: Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer. Epigenetics. 6:610–622. 2011. View Article : Google Scholar : PubMed/NCBI
14	Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
15	Roy S, Shor AC, Bagui TK, Seto E and Pledger WJ: Histone deacetylase 5 represses the transcription of cyclin D3. J Cell Biochem. 104:2143–2154. 2008. View Article : Google Scholar : PubMed/NCBI
16	McKinsey TA, Zhang CL, Lu J and Olson EN: Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 408:106–111. 2000. View Article : Google Scholar : PubMed/NCBI
17	Milde T, Oehme I, Korshunov A, et al: HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 16:3240–3252. 2010. View Article : Google Scholar : PubMed/NCBI
18	Chen J, Xia J, Yu YL, et al: HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression. Tumour Biol. 35:1383–1387. 2013. View Article : Google Scholar : PubMed/NCBI
19	Rana NA and Haltiwanger RS: Fringe benefits: functional and structural impacts of O-glycosylation on the extracellular domain of Notch receptors. Curr Opin Struct Biol. 21:583–589. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ayukawa T, Matsumoto K, Ishikawa HO, et al: Rescue of Notch signaling in cells incapable of GDP-L-fucose synthesis by gap junction transfer of GDP-L-fucose in Drosophila. Proc Natl Acad Sci USA. 109:15318–15323. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hu B, Nandhu MS, Sim H, et al: Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res. 72:3873–3885. 2012. View Article : Google Scholar : PubMed/NCBI
22	Berry N, Gursel DB and Boockvar JA: Notch inhibition via micro-RNA blocks glioma development. Neurosurgery. 70:N20–N22. 2012. View Article : Google Scholar : PubMed/NCBI